On October 6, 2025 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ("Vivoryon" or the"Company"), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, reported that it has completed a private placement of new shares to selected investors ("Offering") with gross proceeds in the amount of EUR 5.1 million (Press release, Vivoryon Therapeutics, OCT 6, 2025, View Source [SID1234656465]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Pursuant to the results of the Offering, the Company will issue 3,380,500new ordinary shares at an offering price of EUR 1.50 per share, amounting to gross proceeds of EUR 5.1 million. The new shares issued pursuant to the Offering represent 12.9 % of Vivoryon’s existing issued share capital and will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights. As a consequence, the Company’s number of shares outstanding will increase to 29,614,337 and the Company’s share capital will increase from EUR 262,338.37 by EUR 33,805.00 to EUR 296,143.37 on completion of the Offering.
The private placement was supported by existing and new shareholders.
"This successful financing demonstrates the trust and confidence of both our longstanding and our new investors in our program and company strategy" said Frank Weber, MD, CEO of Vivoryon. "This is the first time Vivoryon has raised capital for the development of varoglutamstat in chronic kidney disease and it is an important step in moving the project forward including securing a strategic partnership. We are currently in discussions with several pharmaceutical companies, and this additional support provides us with the financial runway and financial flexibility to realize the right collaboration."
The Company intends to use the proceeds from the private placement towards realizing the immediate next steps in ongoing clinical development of its lead candidate varoglutamstat, namely securing a partnership and, if required, additional funding to enable initiation of the planned Phase 2 study in diabetic kidney disease, as well as for general corporate purposes.
The Company now expects, based on its most recent financial and business plan, that its existing cash and cash equivalents including the proceeds from the private placement will be sufficient to fund its operating plans well into Q3 2026.
Koch Wertpapierhandels GmbH supported the private placement, Girolist AG acted as Transfer Agent.
The new shares are expected to be admitted to trading on Euronext Amsterdam on October 7, 2025 with delivery to the investors on or around October 9, 2025. The new shares will rank pari passu in all respects with the existing ordinary shares in the Company.